|
1
|
Kanemoto N: Natural history of primary
pulmonary hypertension elucidated by pulmonary hemodynamics. J
Cardiol. 18:757–763. 1988.(In Japanese). PubMed/NCBI
|
|
2
|
Larsen CM, McCully RB, Murphy JG, Kushwaha
SS, Frantz RP and Kane GC: Usefulness of high-density lipoprotein
cholesterol to predict survival in pulmonary arterial hypertension.
Am J Cardiol. 118:292–297. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen D, Zhou D, Qian J, Chen F, Guan L,
Dong L and Ge J: Atorvastatin prevents dehydromonocrotaline-induced
pulmonary hypertension in beagles. Exp Lung Res. 38:333–343. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maron DJ, Fazio S and Linton MF: Current
perspectives on statins. Circulation. 101:207–213. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li XL, Guan RJ and Li JJ: Attenuation of
monocrotaline-induced pulmonary arterial hypertension in rats by
rosuvastatin. J Cardiovasc Pharmacol. 60:219–226. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nishimura T, Vaszar LT, Faul JL, Zhao G,
Berry GJ, Shi L, Qiu D, Benson G, Pearl RG and Kao PN: Simvastatin
rescues rats from fatal pulmonary hypertension by inducing
apoptosis of neointimal smooth muscle cells. Circulation.
108:1640–1645. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Murata T, Kinoshita K, Hori M, Kuwahara M,
Tsubone H, Karaki H and Ozaki H: Statin protects endothelial nitric
oxide synthase activity in hypoxia-induced pulmonary hypertension.
Arterioscler Thromb Vasc Biol. 25:2335–2342. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mason RP, Walter MF, Day CA and Jacob RF:
Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a
reductase inhibitors contribute to distinct pharmacologic and
pleiotropic actions. Am J Cardiol. 96:11F–23F. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rakotoniaina Z, Guerard P, Lirussi F,
Goirand F, Rochette L, Dumas M and Bardou M: The protective effect
of HMG-CoA reductase inhibitors against monocrotaline-induced
pulmonary hypertension in the rat might not be a class effect:
Comparison of pravastatin and atorvastatin. Naunyn Schmiedebergs
Arch Pharmacol. 374:195–206. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Satoh K, Fukumoto Y, Nakano M, Sugimura K,
Nawata J, Demachi J, Karibe A, Kagaya Y, Ishii N, Sugamura K and
Shimokawa H: Statin ameliorates hypoxia-induced pulmonary
hypertension associated with down-regulated stromal cell-derived
factor-1. Cardiovasc Res. 81:226–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Achcar RO, Demura Y, Rai PR,
Taraseviciene-Stewart L, Kasper M, Voelkel NF and Cool CD: Loss of
caveolin and heme oxygenase expression in severe pulmonary
hypertension. Chest. 129:696–705. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chan SY and Loscalzo J: Pathogenic
mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol.
44:14–30. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Zhao B, Chen Y, Ma L, Chen EZ and
Mao EQ: Inflammation and edema in the lung and kidney of
hemorrhagic shock rats are alleviated by biliary tract external
drainage via the heme oxygenase-1 pathway. Inflammation.
38:2242–2251. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zuckerbraun BS, Chin BY, Wegiel B, Billiar
TR, Czsimadia E, Rao J, Shimoda L, Ifedigbo E, Kanno S and
Otterbein LE: Carbon monoxide reverses established pulmonary
hypertension. J Exp Med. 203:2109–2119. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Adam O and Laufs U: Antioxidative effects
of statins. Arch Toxicol. 82:885–892. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Steinberg D: The statins in preventive
cardiology. N Engl J Med. 359:1426–1427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nishimura T, Faul JL, Berry GJ, Vaszar LT,
Qiu D, Pearl RG and Kao PN: Simvastatin attenuates smooth muscle
neointimal proliferation and pulmonary hypertension in rats. Am J
Respir Crit Care Med. 166:1403–1408. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu H, Sung A, Zhao G, Shi L, Qiu D,
Nishimura T and Kao PN: Simvastatin enhances bone morphogenetic
protein receptor type II expression. Biochem Biophys Res Commun.
339:59–64. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kao PN: Simvastatin treatment of pulmonary
hypertension: An observational case series. Chest. 127:1446–1452.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pei Y, Ma P, Wang X, Zhang W, Zhang X,
Zheng P, Yan L, Xu Q and Dai G: Rosuvastatin attenuates
monocrotaline-induced pulmonary hypertension via regulation of
Akt/eNOS signaling and asymmetric dimethylarginine metabolism. Eur
J Pharmacol. 666:165–172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yao J, Xiong M, Tang B, Chen G, Liang M,
Ma X, Wang Z and Wu Z: Simvastatin attenuates pulmonary vascular
remodelling by down-regulating matrix metalloproteinase-1 and −9
expression in a carotid artery-jugular vein shunt pulmonary
hypertension model in rats. Eur J Cardiothorac Surg. 42:e121–e127.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Carlin CM, Celnik DF, Pak O, Wadsworth R,
Peacock AJ and Welsh DJ: Low-dose fluvastatin reverses the hypoxic
pulmonary adventitial fibroblast phenotype in experimental
pulmonary hypertension. Am J Respir Cell Mol Biol. 47:140–148.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Campian ME, Hardziyenka M, Michel MC and
Tan HL: How valid are animal models to evaluate treatments for
pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol.
373:391–400. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jeffery TK and Morrell NW: Molecular and
cellular basis of pulmonary vascular remodeling in pulmonary
hypertension. Prog Cardiovasc Dis. 45:173–202. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
van Deurs B, Roepstorff K, Hommelgaard AM
and Sandvig K: Caveolae: Anchored, multifunctional platforms in the
lipid ocean. Trends Cell Biol. 13:92–100. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Razani B, Engelman JA, Wang XB, Schubert
W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, et
al: Caveolin-1 null mice are viable but show evidence of
hyperproliferative and vascular abnormalities. J Biol Chem.
276:38121–38138. 2001.PubMed/NCBI
|
|
27
|
Mathew R, Huang J, Shah M, Patel K, Gewitz
M and Sehgal PB: Disruption of endothelial-cell
caveolin-1alpha/raft scaffolding during development of
monocrotaline-induced pulmonary hypertension. Circulation.
110:1499–1506. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bouzas B and Gatzoulis MA: Pulmonary
arterial hypertension in adults with congenital heart disease. Rev
Esp Cardiol. 58:465–469. 2005.(In Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Machado RF: Sickle cell anemia-associated
pulmonary arterial hypertension. J Bras Pneumol. 33:583–591.
2007.(In English, Portuguese). View Article : Google Scholar : PubMed/NCBI
|
